6533b828fe1ef96bd1287b03

RESEARCH PRODUCT

Grey Matter Microstructural Integrity Alterations in Blepharospasm Are Partially Reversed by Botulinum Neurotoxin Therapy.

Günther DeuschlBurcu PaktasKirsten E. ZeunerMuthuraman MuthuramanNabin KoiralaHanganu AlexandruVenkata C. ChirumamillaSergiu Groppa

subject

0301 basic medicineCentral Nervous SystemMaleMovement disordersBotulinum ToxinsBlepharospasmlcsh:MedicineToxicologyPathology and Laboratory MedicineNervous SystemDiagnostic Radiology0302 clinical medicineMaterials PhysicsMedicine and Health SciencesToxinsLongitudinal StudiesGray Matterlcsh:ScienceMicrostructureMultidisciplinaryMovement DisordersRadiology and ImagingPhysicsMotor CortexBrainNeurodegenerative DiseasesAnatomyMiddle AgedMagnetic Resonance ImagingPathophysiologyBotulinum neurotoxinFacial musclesDystoniamedicine.anatomical_structureTreatment OutcomeNeurologyPhysical SciencesFemalePrimary motor cortexmedicine.symptomAnatomyResearch ArticleAdultmedicine.medical_specialtyImaging TechniquesBlepharospasmToxic AgentsBacterial ToxinsMaterials ScienceBotulinum ToxinGrey matterResearch and Analysis Methods03 medical and health sciencesDiagnostic MedicineOphthalmologymedicineHumansHemifacial SpasmDemographyAgedbusiness.industrylcsh:RBiology and Life SciencesCorrectionmedicine.disease030104 developmental biologyCross-Sectional StudiesFacePeople and Placeslcsh:QbusinessHead030217 neurology & neurosurgeryHemifacial spasm

description

OBJECTIVE Benign Essential Blepharospasm (BEB) and hemifacial spasm (HFS) are the most common hyperkinetic movement disorders of facial muscles. Although similar in clinical presentation different pathophysiological mechanisms are assumed. Botulinum Neurotoxin (BoNT) is a standard evidence-based treatment for both conditions. In this study we aimed to assess grey matter microstructural differences between these two groups of patients and compared them with healthy controls. In patients we furthermore tracked the longitudinal morphometric changes associated with BoNT therapy. We hypothesized microstructural differences between the groups at the time point of maximum symptoms representation and distinct longitudinal grey matter dynamics with symptom improvement. METHODS Cross-sectional and longitudinal analyses of 3T 3D-T1 MRI images from BEB, HFS patients prior to and one month after BoNT therapy and from a group of age and sex matched healthy controls. Cortical thickness as extracted from Freesurfer was assessed as parameter of microstructural integrity. RESULTS BoNT therapy markedly improved motor symptoms in patients with BEB and HFS. Significant differences of grey matter integrity have been found between the two patients groups. The BEB group showed lower cortical thickness at baseline in the frontal-rostral, supramarginal and temporal regions compared to patients with HFS. In this group BoNT treatment was associated with a cortical thinning in the primary motor cortex and the pre-supplementary motor area (pre-SMA). Contrary patients with HFS showed no longitudinal CT changes. A decreased cortical thickness was attested bilaterally in the temporal poles and in the right superior frontal region in BEB patients in comparison to HC. Patients in the HFS group presented a decreased CT in the left lingual gyrus and temporal pole. CONCLUSIONS Although patients with BEB and HFS present clinically with involuntary movements of facial muscles, they exhibited differences in cortical thickness. While BoNT therapy was equally effective in both groups, widespread changes of cortical morphology occurred only in BEB patients. We demonstrated specific disease- and therapy-dependent structural changes induced by BoNT in the studied hyperkinetic conditions.

10.1371/journal.pone.0168652https://pubmed.ncbi.nlm.nih.gov/28192485